Jefferies puts SkyePharma at buy

SkyePharma plc was rated at buy by Jefferies & Co., Inc. analyst Robin Campbell on full-year 2005 results. The analyst sees the share price remaining tied to the company's ability to deliver on its new strategy. A focus on disposals and delivering products could hold the key. Shares of the London pharmaceutical company were up 7 cents, or 1.04%, at $6.80 on volume of 12,333 shares versus the three-month running average of 24,950 shares. (NYSE: SKYE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.